Fig. 4. (A ) Western blots of the effects of oxygen and glucose deprivation (OGD) and dexmedetomidine postconditioning on active caspase 3 (P¹⁷caspase 3) and actin immunoreactivity (β-actin). (B ) Effects of the α2-adrenoceptor inhibitor yohimbine (yoh: 100 μm), the Src kinases inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2, 5 μm), the inhibitor of the PI3-Kinase wortmanin (Wort: 100 nm), the imidazoline receptors antagonist 1 efaroxan (Efa: 10⁻⁵M), the MEK inhibitor PD 098059 (PD: 5 μm), the mitochondrial ATP dependant K channel 5-hydroxydecanoic acid (5HD: 10 μm), and their combination on dexmedetomidine-induced postconditioning after 60 min of OGD-induced increase in active caspase 3 (P¹⁷caspase 3) expression in the CA1 subfield area of mouse organotypic slices cultures. Data (mean ± SD) are expressed as a fractional of P¹⁷caspase 3 on actin immunoreactivity increase from control (control: 100%). ANOVA for P17 cspase 3 was F = 77.34, P < 0.0001. Post hoc  analysis used Bonferroni correction. NS = nonsignificant; ***P < 0.0001 versus  control; ♦♦♦P < 0.001 versus  60 min of OGD.